Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: Technical recommendations

Riccardo Lencioni, Camillo Aliberti, Thierry De Baere, Ricardo Garcia-Monaco, Govindarajan Narayanan, Elizabeth O'Grady, William S. Rilling, Duncan Walker, Robert C.G. Martin

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

Transcatheter hepatic arterial administration of irinotecan-loaded drug-eluting beads (DEBIRI) is used to treat liver-only or liver-dominant metastatic disease from colorectal cancer (CRC). Eligibility for DEBIRI should be established in each individual patient by a multidisciplinary team based on comprehensive clinical, imaging, and laboratory assessment. Standardization of DEBIRI technique and protocols would be expected to lead to improved efficacy and safety. The present article provides a set of technical recommendations for the use of DEBIRI in the treatment of hepatic CRC metastases.

Original languageEnglish (US)
Pages (from-to)365-369
Number of pages5
JournalJournal of Vascular and Interventional Radiology
Volume25
Issue number3
DOIs
StatePublished - 2014

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: Technical recommendations'. Together they form a unique fingerprint.

Cite this